|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hotta K, Fujiwara Y, Matsuo K, Suzuki T,
Kiura K, Tabata M, Takigawa N, Ueoka H and Tanimoto M: Recent
improvement in the survival of patients with advanced nonsmall cell
lung cancer enrolled in phase III trials of first-line, systemic
chemotherapy. Cancer. 109:939–948. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peters S, Adjei AA, Gridelli C, Reck M,
Kerr K and Felip E; ESMO Guidelines Working Group, : Metastatic
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23
Suppl 7:vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arteaga CL: The epidermal growth factor
receptor: From mutant oncogene in nonhuman cancers to therapeutic
target in human neoplasia. J Clin Oncol. 19 18 Suppl:32S–40S.
2001.PubMed/NCBI
|
|
5
|
Gatzemeier U, Pluzanska A, Szczesna A,
Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H,
Pesek M, Serwatowski P, et al: Phase III study of erlotinib in
combination with cisplatin and gemcitabine in advanced
non-small-cell lung cancer: The Tarceva Lung Cancer Investigation
Trial. J Clin Oncol. 25:1545–1552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS, Prager D, Hermann R,
Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P,
Li X, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride
(OSI-774) combined with carboplatin and paclitaxel chemotherapy in
advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilson KJ, Gilmore JL, Foley J, Lemmon MA
and Riese DJ II: Functional selectivity of EGF family peptide
growth factors: Implications for cancer. Pharmacol Ther. 122:1–8.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laurent-Puig P, Lievre A and Blons H:
Mutations and response to epidermal growth factor receptor
inhibitors. Clin Cancer Res. 15:1133–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kancha RK, von Bubnoff N, Peschel C and
Duyster J: Functional analysis of epidermal growth factor receptor
(EGFR) mutations and potential implications for EGFR targeted
therapy. Clin Cancer Res. 15:460–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jackman DM, Yeap BY, Sequist LV, Lindeman
N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS,
et al: Exon 19 deletion mutations of epidermal growth factor
receptor are associated with prolonged survival in non-small cell
lung cancer patients treated with gefitinib or erlotinib. Clin
Cancer Res. 12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jackman D, Pao W, Riely GJ, Engelman JA,
Kris MG, Jänne PA, Lynch T, Johnson BE and Miller VA: Clinical
definition of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun JM, Ahn MJ, Choi YL, Ahn JS and Park
K: Clinical implications of T790M mutation in patients with
acquired resistance to EGFR tyrosine kinase inhibitors. Lung
Cancer. 82:294–298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ayoola A, Barochia A, Belani K and Belani
CP: Primary and acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small cell lung cancer:
An update. Cancer Invest. 30:433–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:pp. 20932–20937. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ohashi K, Sequist LV, Arcila ME, Moran T,
Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et
al: Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS,
NRAS, or MEK1. Proc Natl Acad Sci USA. 109:pp. E2127–E2133. 2012;
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Serizawa M, Takahashi T, Yamamoto N and
Koh Y: Genomic aberrations associated with erlotinib resistance in
non-small cell lung cancer cells. Anticancer Res. 33:5223–5233.
2013.PubMed/NCBI
|
|
22
|
Takezawa K, Pirazzoli V, Arcila ME, Nebhan
CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ,
Melnick MA, et al: HER2 amplification: A potential mechanism of
acquired resistance to EGFR inhibition in EGFR mutant lung cancers
that lack the second-site EGFRT790M mutation. Cancer Discov.
2:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur
C, Sun J, Li L, Kowluru A and Chen F: Gefitinib resistance resulted
from STAT3-mediated Akt activation in lung cancer cells.
Oncotarget. 4:2430–2438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR TKI therapy in 155 patients with EGFR mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nature Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko
TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, et al: A
common BIM deletion polymorphism mediates intrinsic resistance and
inferior responses to tyrosine kinase inhibitors in cancer. Nat
Med. 18:521–528. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakagawa T, Takeuchi S, Yamada T, Ebi H,
Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y and Yano
S: EGFR-TKI resistance due to BIM polymorphism can be circumvented
in combination with HDAC inhibition. Cancer Res. 73:2428–2434.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Costa DB, Halmos B, Kumar A, Schumer ST,
Huberman MS, Boggon TJ, Tenen DG and Kobayashi S: BIM mediates EGFR
tyrosine kinase inhibitor-induced apoptosis in lung cancers with
oncogenic EGFR mutations. PLoS Med. 4:1669–1680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cragg MS, Kuroda J, Puthalakath H, Huang
DC and Strasser A: Gefitinib-induced killing of NSCLC cell lines
expressing mutant EGFR requires BIM and can be enhanced by BH3
mimetics. PLoS Med. 4:1681–1690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Faber AC, Corcoran RB, Ebi H, Sequist LV,
Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, et
al: BIM expression in treatment-naive cancers predicts
responsiveness to kinase inhibitors. Cancer Discov. 1:352–365.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gong Y, Somwar R, Politi K, Balak M,
Chmielecki J, Jiang X and Pao W: Induction of BIM is essential for
apoptosis triggered by EGFR kinase inhibitors in mutant
EGFR-dependent lung adenocarcinomas. PLoS Med. 4:e2942007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Benedettini E, Sholl LM, Peyton M, Reilly
J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al:
Met activation in non-small cell lung cancer is associated with de
novo resistance to EGFR inhibitors and the development of brain
metastasis. Am J Pathol. 177:415–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balak MN, Gong Y, Riely GJ, Somwar R, Li
AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, et al:
Novel D761Y and common secondary T790M mutations in epidermal
growth factor receptor-mutant lung adenocarcinomas with acquired
resistance to kinase inhibitors. Clin Cancer Res. 12:6494–6501.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kosaka T, Yatabe Y, Endoh H, Yoshida K,
Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer and acquired resistance to gefitinib.
Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen L, Willis SN, Wei A, Smith BJ,
Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC:
Differential targeting of prosurvival Bcl-2 proteins by their
BH3-only ligands allows complementary apoptotic function. Mol Cell.
17:393–403. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
O'Connor L, Strasser A, O'Reilly LA,
Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of
the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Özvegy-Laczka C, Cserepes J, Elkind NB and
Sarkadi B: Tyrosine kinase inhibitor resistance in cancer: Role of
ABC multidrug transporters. Drug Resist Updat. 8:15–26. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jonker JW, Buitelaar M, Wagenaar E, van
der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink
RP, Rosing H, et al: The breast cancer resistance protein protects
against a major chlorophyll-derived dietary phototoxin and
protoporphyria. Proc Natl Acad Sci USA. 99:pp. 15649–15654. 2002;
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Allen JD and Schinkel AH: Multidrug
resistance and pharmacological protection mediated by the breast
cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 1:427–434.
2002.PubMed/NCBI
|
|
43
|
Engelman JA, Jänne PA, Mermel C, Pearlberg
J, Mukohara T, Fleet C, Cichowski K, Johnson BE and Cantley LC:
ErbB-3 mediates phosphoinositide 3-kinase activity in
gefitinib-sensitive non-small cell lung cancer cell lines. Proc
Natl Acad Sci USA. 102:pp. 3788–3793. 2005; View Article : Google Scholar : PubMed/NCBI
|
